Rhizomelic chondrodysplasia punctata | |
---|---|
Low levels of plasmalogens is a characteristic of rhizomelic chondrodysplasia punctata. | |
Specialty | Medical genetics |
Symptoms | Alopecia, flat face |
Causes | PEX7 gene, GNPAT gene and AGPS gene mutations |
Diagnostic method | Clinical and radiologic finding |
Treatment | Physical therapy |
Rhizomelic chondrodysplasia punctata is a rare developmental brain disorder characterized by abnormally short arms and legs (rhizomelia), seizures, recurrent respiratory tract infections and congenital cataracts.
The cause is a genetic mutation that results in low levels of plasmalogens, which are a type of lipid found in cell membranes throughout the body, but whose function is not known.
Signs and symptoms
Rhizomelic chondrodysplasia punctata has the following symptoms:
- Bilateral shortening of the femur, resulting in short legs
- Post-natal growth problems (deficiency)
- Cataracts
- Intellectual disability
- Possible seizures
- Possible infections of respiratory tract
Genetics
This condition is a consequence of mutations in the PEX7 gene, the GNPAT gene (which is located on chromosome 1) or the AGPS gene. The condition is acquired in an autosomal recessive manner.
Pathophysiology
The mechanism of rhizomelic chondrodysplasia punctata in the case of type 1 of this condition involves a defect in PEX7, whose product is involved in peroxisome assembly. There are 3 pathways that depend on peroxisomal biogenesis factor 7 activities, including:
- AGPS (catalyzes plasmalogen biosynthesis)
- PhYH (catalyzes catabolism of phytanic acid)
- ACAA1 (catalyzes beta-oxidation of VLCFA - straight)
Diagnosis
The diagnosis of rhizomelic chondrodysplasia punctata can be based on genetic testing as well as radiography results, plus a physical examination of the individual.
Types
- Type 1 (RCDP1) is associated with PEX7 mutations; these are peroxisome biogenesis disorders where proper assembly of peroxisomes is impaired.
- Type 2 (RCDP2) is associated with DHAPAT mutations.
- Type 3 (RCDP3) is associated with AGPS mutations.
Treatment
Management of rhizomelic chondrodysplasia punctata can include physical therapy; additionally orthopedic procedures improved function sometimes in affected people.
Prognosis
The prognosis is poor in this condition, and most children die before the age of 10. However, some survive to adulthood, especially if they have a non-classical (mild) form of RCDP.
Children with classical, or severe, RCDP1 have severe developmental disabilities. Most of them achieve early developmental skills, such as smiling, but they will not develop skills expected from a baby older than six months (such as feeding themselves or walking). By contrast, children with non-classical mild RCDP1 often learn to walk and talk.
See also
References
- ^ "Rhizomelic chondrodysplasia punctata type 1". Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. US National Library of Medicine. Archived from the original on 24 January 2017. Retrieved 23 January 2017.
- ^ Reference, Genetics Home. "rhizomelic chondrodysplasia punctata". Genetics Home Reference. Archived from the original on 2016-12-24. Retrieved 2017-01-16.
- ^ "Rhizomelic chondrodysplasia punctata". Orphanet. Archived from the original on 2 February 2017. Retrieved 23 January 2017.
- ^ Braverman, Nancy E.; Moser, Ann B.; Steinberg, Steven J. (2020). "Rhizomelic Chondrodysplasia Punctata Type 1". GeneReviews. PMID 20301447. NBK1270. Archived from the original on 2017-01-18. Retrieved 2017-01-16.
- Brodsky, Michael C. (2016-06-28). Pediatric Neuro-Ophthalmology. Springer. p. 620. ISBN 9781493933846. Archived from the original on 2023-01-11. Retrieved 2020-11-21.
- "Rhizomelic chondrodysplasia punctata type 1". Genetics Testing Laboratory (GTR): Conditions. US National Library of Medicine. Archived from the original on 8 February 2017. Retrieved 23 January 2017.
- Online Mendelian Inheritance in Man (OMIM): Rhizomelic Chondrodysplasia Punctata, Type 2; RCDP2 - 222765
- Online Mendelian Inheritance in Man (OMIM): Rhizomelic Chondrodysplasia Punctata, Type 3; RCDP3 - 600121
Further reading
- Benacerraf, Beryl (2007). Ultrasound of fetal syndromes (2nd ed.). Philadelphia: Churchill Livingstone / Elsevier. ISBN 978-0443066412. Archived from the original on 11 January 2023. Retrieved 23 January 2017.
- Ashwal, Stephen; Ferriero, Donna M.; Schor, Nina F. (2012). Swaiman, Kenneth F. (ed.). Swaiman's pediatric neurology principles and practice (5th ed.). : Elsevier Saunders. ISBN 978-0323089111. Archived from the original on 11 January 2023. Retrieved 23 January 2017.
- Braverman NE, Steinberg SJ, Fallatah W, et al. (2020). Adam MP, Ardinger HH, Pagon RA, et al. (eds.). "Rhizomelic Chondrodysplasia Punctata Type 1". GeneReviews® . University of Washington. PMID 20301447. NBK1270. Archived from the original on 2017-01-18. Retrieved 2017-01-16.
- Braverman NE, Bober MB, Brunetti-Pierri N, et al. (2020). Adam MP, Ardinger HH, Pagon RA, et al. (eds.). "Chondrodysplasia Punctata 1, X-Linked". GeneReviews® . University of Washington. PMID 20301713. Archived from the original on 2022-03-09. Retrieved 2022-03-09.
- Kumble S, Savarirayan R (2020). Adam MP, Ardinger HH, Pagon RA, et al. (eds.). "Chondrodysplasia Punctata 2, X-Linked". GeneReviews® . University of Washington. PMID 21634086. NBK55062. Archived from the original on 2020-08-05. Retrieved 2022-03-09.
External links
Classification | D |
---|---|
External resources |
Genetic disorder, organelle: Peroxisomal disorders and lysosomal structural disorders | |
---|---|
Peroxisome biogenesis disorder | |
Enzyme-related | |
Transporter-related | |
Lysosomal | |
See also: proteins, intermediates |